Anna Rivkin
Chief Business Officer Foghorn Therapeutics
Anna Rivkin, PHD joined Foghorn as Chief Business Officer (CBO) in September 2024. Before joining Foghorn, Anna most recently held leadership roles at Bristol Myers Squibb (BMS) where she successfully oversaw strategic transactions across immunology, neuroscience, and cardiovascular disease as the Vice President of Business Development. Anna helped evolve the BMS pipeline including leading high-impact deals such as the $14 billion purchase of Karuna Therapeutics and the $13 billion purchase of MyoKardia Therapeutics. Prior to BMS, Anna worked at Merck & Co., holding a number of roles of increasing responsibilities in business development and clinical research. Anna received her Ph.D. in Neuroscience from Case Western Reserve University and holds a B.A. from Johns Hopkins University.
Seminars
- What new capabilities are pharma looking for from a partnership? Are platform deals of interest?
- Glues, bifunctionals, antibody-degrader conjugates: what are the considerations when discussing these technologies? What evidence would make a DAC asset “partnerable”?
- Are there unique challenges when discussing degradation within large pharma that you don’t see when modalities have more clinical validation?
